Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach

Around 3–7% of patients with non-small cell lung cancer (NSCLC), which represent 85% of diagnosed lung cancers, have a rearrangement in the ALK gene that produces an abnormal activity of the ALK protein cell signaling pathway. The developed ALK tyrosine kinase inhibitors (TKIs), such as crizotinib,...

Descripción completa

Detalles Bibliográficos
Autores principales: Carcereny, Enric, Fernández-Nistal, Alonso, López, Araceli, Montoto, Carmen, Naves, Andrea, Segú-Vergés, Cristina, Coma, Mireia, Jorba, Guillem, Oliva, Baldomero, Mas, Jose Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899557/
https://www.ncbi.nlm.nih.gov/pubmed/33659043
http://dx.doi.org/10.18632/oncotarget.27875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899557/
https://www.ncbi.nlm.nih.gov/pubmed/33659043
http://dx.doi.org/10.18632/oncotarget.27875

Ejemplares similares